Paper36551663
HER3 Alterations in Cancer and Potential Clinical Implications.
Kilroy MK and 6 others. Cancers (Basel), 2022. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. HER3 Alterations in Cancer and Potential Clinical Implications. Papers, record 36551663. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36551663
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 1016616 | American Cancer Society | PubMed |
Source PubMed
References149
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18259690 | The epidermal growth factor receptor family: biology driving targeted therapeutics. | Cell Mol Life Sci | 2008 | https://conductscience.org/library/papers/18259690 | PubMed |
| 2 | 29383036 | Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. | Ther Adv Med Oncol | 2018 | https://conductscience.org/library/papers/29383036 | PubMed |
| 3 | 32847130 | Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32847130 | PubMed |
| 4 | 25891541 | Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. | Lung Cancer | 2015 | https://conductscience.org/library/papers/25891541 | PubMed |
| 5 | 31548545 | Breast cancer. | Nat Rev Dis Primers | 2019 | https://conductscience.org/library/papers/31548545 | PubMed |
| 6 | 35625959 | Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35625959 | PubMed |
| 7 | 14623113 | Shc-dependent pathway is redundant but dominant in MAPK cascade activation by EGF receptors: a modeling inference. | FEBS Lett | 2003 | https://conductscience.org/library/papers/14623113 | PubMed |
| 8 | 24300455 | HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome. | Eur J Cancer | 2014 | https://conductscience.org/library/papers/24300455 | PubMed |
| 9 | 26689995 | Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer. | Oncotarget | 2016 | https://conductscience.org/library/papers/26689995 | PubMed |
| 10 | 32034073 | Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32034073 | PubMed |
| 11 | 32080212 | Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. | Sci Rep | 2020 | https://conductscience.org/library/papers/32080212 | PubMed |
| 12 | 30975923 | Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. | Oncologist | 2019 | https://conductscience.org/library/papers/30975923 | PubMed |
| 13 | 35839938 | Targeting HER3-dependent activation of nuclear AKT improves radiotherapy of non-small cell lung cancer. | Radiother Oncol | 2022 | https://conductscience.org/library/papers/35839938 | PubMed |
| 14 | 34320350 | ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. | Cell Rep | 2021 | https://conductscience.org/library/papers/34320350 | PubMed |
| 15 | 10880430 | The ErbB signaling network: receptor heterodimerization in development and cancer. | EMBO J | 2000 | https://conductscience.org/library/papers/10880430 | PubMed |
| 16 | 34548309 | Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. | Cancer Discov | 2022 | https://conductscience.org/library/papers/34548309 | PubMed |
| 17 | 33750895 | Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer. | Oncogene | 2021 | https://conductscience.org/library/papers/33750895 | PubMed |
| 18 | 31519989 | ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. | Oncogene | 2020 | https://conductscience.org/library/papers/31519989 | PubMed |
| 19 | 24667376 | Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. | Sci Signal | 2014 | https://conductscience.org/library/papers/24667376 | PubMed |
| 20 | 34084213 | HER3 expression and MEK activation in non-small-cell lung carcinoma. | Lung Cancer Manag | 2021 | https://conductscience.org/library/papers/34084213 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42449909 | Tracking Bone Loss in GLP-1RA Therapy: The Potential of the Deoxypyridinoline Urine Test. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42449909 | PubMed |
| 41114412 | Antibody-drug conjugates in the treatment of advanced triple-negative breast cancer. | Prz Menopauzalny | 2025 | https://conductscience.org/library/papers/41114412 | PubMed |
| 40433388 | Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions. | Front Immunol | 2025 | https://conductscience.org/library/papers/40433388 | PubMed |
| 40290122 | HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway. | Genes Dis | 2025 | https://conductscience.org/library/papers/40290122 | PubMed |
| 40123590 | Colorectal Cancer: Risk Factors, Novel Approaches in Molecular Screening and Treatment. | Int J Mol Cell Med | 2025 | https://conductscience.org/library/papers/40123590 | PubMed |
| 40108093 | Establishment and characterization of novel patient-derived esophageal tumoroids with long-term cultivability. | Hum Cell | 2025 | https://conductscience.org/library/papers/40108093 | PubMed |
| 40087402 | Emerging importance of HER3 in tumorigenesis and cancer therapy. | Nat Rev Clin Oncol | 2025 | https://conductscience.org/library/papers/40087402 | PubMed |
| 39984637 | Systemic HER3 ligand-mimicking nanobioparticles enter the brain and reduce intracranial tumour growth. | Nat Nanotechnol | 2025 | https://conductscience.org/library/papers/39984637 | PubMed |
| 39147936 | Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies. | Clin Transl Oncol | 2025 | https://conductscience.org/library/papers/39147936 | PubMed |
| 38473386 | Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38473386 | PubMed |
| 38239350 | Targeting HER3 to overcome EGFR TKI resistance in NSCLC. | Front Immunol | 2023 | https://conductscience.org/library/papers/38239350 | PubMed |
| 38231075 | The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study. | Curr Med Chem | 2025 | https://conductscience.org/library/papers/38231075 | PubMed |
| 38200149 | SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs. | Acta Pharmacol Sin | 2024 | https://conductscience.org/library/papers/38200149 | PubMed |
| 38023167 | Triple-negative breast cancer: from none to multiple therapeutic targets in two decades. | Front Oncol | 2023 | https://conductscience.org/library/papers/38023167 | PubMed |
Genes45
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36551663
GET https://conductscience.org/api/papers/v1/36551663/references?page=2